HOUSTON--(BW HealthWire)--July 29, 2002--Himalaya USA announces that the results of a phase III open clinical trial of Menotab (also known in the USA as MenoCare), a herbal formula of The Himalaya Drug Company, were recently published in the prestigious medical journal The Antiseptic (Vol. 98, No. 3, pp. 87-89) and confirmed earlier data on the efficacy of Menotab in mitigating all unpleasant menopausal symptoms.
In the study conducted at the department of OBG of the Ramiah Medical College Hospital in Bangalore, India, 28 postmenopausal women were treated with Menotab taken daily for a period of three months. Occurrences of hot flashes decreased by 96.2%, night sweating by 100%, insomnia by 71%.
These positive clinical results on a menopause herbal treatment were obtained without any side-effects and the safety of this phytopharmaceutical product was established through earlier experimental studies.
"These results are especially welcome in the midst of the controversy surrounding hormone replacement therapies and their long term risks. It offers women a safe and effective alternative," says Dr. Philip Duterme, president and chief executive officer of Himalaya USA.
"Scientific evidence of safety and efficacy of herbal remedies, along with manufacturing practices that ensure their consistency, are critical to alleviate women's concerns about their quality. Since 1930, Himalaya has been at the forefront of marketing true pharma grade products that are developed, tested and produced to pharmaceutical standards," Duterme adds. "Menotab (MenoCare) is one of these, as is the world renowned Liv.52."
Himalaya USA, headquartered in Houston, Texas, is the exclusive representative in North America of The Himalaya Drug Company, a world leading phytopharmaceutical company. Founded in 1930 and located in Bangalore, India, Himalaya has pioneered a science-based and pharma grade herbal medicine.
For more information on Himalaya and MenoCare(R), please visit our Web site at www.himalayausa.com.